Kamada (KMDA): Phase II Trial Adds Support For Inhaled AAT Therapy - Jefferies

August 31, 2016 8:53 AM EDT
Get Alerts KMDA Hot Sheet
Price: $6.05 -2.42%

Rating Summary:
    2 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 22 | Down: 32 | New: 34
Trade KMDA Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, Raj Denjoy, reiterated his Buy rating on shares of Kamada Ltd. (NASDAQ: KMDA) after the company reported Phase II US trial results for inhaled AAT. The analyst believes that the trial showed statistically significant increases of both AAT & ANEC levels in the lung compared to the placebo. While the study was not designed to show clinical benefits, it showed that inhaled AAT effectively reaches lung tissue, where AAT deficiency manifests over time as worsening lung function. As such, the trail lends crucial support to a mid-17 EU approval and continuing the US clinical program.

No change to the price target of $7.

For an analyst ratings summary and ratings history on Kamada Ltd. click here. For more ratings news on Kamada Ltd. click here.

Shares of Kamada Ltd. closed at $4.89 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Jefferies & Co

Add Your Comment